Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Liabilities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Total Liabilities for 13 consecutive years, with $656.9 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 128.2% to $656.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $656.9 million through Dec 2025, up 128.2% year-over-year, with the annual reading at $656.9 million for FY2025, 128.2% up from the prior year.
  • Total Liabilities for Q4 2025 was $656.9 million at Madrigal Pharmaceuticals, down from $736.7 million in the prior quarter.
  • The five-year high for Total Liabilities was $736.7 million in Q3 2025, with the low at $49.2 million in Q1 2021.
  • Average Total Liabilities over 5 years is $233.3 million, with a median of $207.3 million recorded in 2023.
  • The sharpest move saw Total Liabilities increased 21.97% in 2024, then surged 148.8% in 2025.
  • Over 5 years, Total Liabilities stood at $77.2 million in 2021, then soared by 113.9% to $165.2 million in 2022, then skyrocketed by 42.4% to $235.2 million in 2023, then rose by 22.38% to $287.9 million in 2024, then surged by 128.2% to $656.9 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $656.9 million, $736.7 million, and $319.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.